BACKThings are slowly beginning to move ahead on our project to cure Alzheimer’s disease. It’s clear that not only is the role of microglia slowly becoming accepted, but there are more and more investors who see an opportunity to help move biotech and medicine from the old paradigm (BAPP and Tau cause disease) to the […]
Telocyte Begins
Things are slowly beginning to move ahead on our project to cure Alzheimer’s disease. It’s clear that not only is the role of microglia slowly becoming accepted, but there are more and more investors who see an opportunity to help move biotech and medicine from the old paradigm (BAPP and Tau cause disease) to the new paradigm (cell senescence triggers a far more complex cascade than we had once thought). One example of this shift is the recent review by Boccardi et al (Boccardi V, Pelini L, Ercolani S, Ruggiero C, Mecocci P. From cell senescence to Alzheimer’s disease: the role of telomere shortening. Ageing Research Reviews 22:1-8, 2015). On a personal note, we now have investors pushing us to move ahead with our Telocyte project and we have a commitment from one of the leading research organizations in the world to form a collaborative effort. Our intent is to move ahead with the remaining animal trials necessary to get an IND, then commence FDA-sponsored human trials. Those of you who are interested in either helping our effort or being on a registry of potential patients with early Alzheimer’s may contact me.
- Aging diseases (58)
- Alzheimer's disease (55)
- Big Pharma (3)
- Biotech (11)
- BioViva (3)
- Book (1)
- Cancer (2)
- Dementia (1)
- Epigenetics (20)
- microglia (13)
- mitochondria (13)
- monoclonal antibodies (2)
- Osteoarthritis (10)
- Osteoporosis (7)
- progeria (6)
- senescent cells (24)
- solanezumab (5)
- Telocyte (16)
- Telomerase (26)
- Telomeres (29)
- The Telomerase Revolution (11)